Search clinical trials for: AL001

Total 56 results

Alector Inc.

Active, not recruiting

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Frontotemporal Dementia

Spain, United States, Portugal, United Kingdom, France, Germany, Netherlands, Belgium, Australia, Italy, Turkey, Switzerland, Argentina, Canada, Greece, Sweden
Alector Inc.

Active, not recruiting

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Frontotemporal Dementia

Canada, United States, Germany, United Kingdom, Italy, Netherlands
Alector Inc.
GlaxoSmithKline

Enrolling by invitation

Continuation Study for Latozinemab

Neurodegenerative Diseases

Canada, United States, Belgium, France, Spain, Portugal, Germany, Italy, Netherlands, Sweden, United Kingdom
Alector Inc.

Terminated

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Amyotrophic Lateral Sclerosis

United States
Zhongnan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Akeso Biopharma Co., Ltd.

Recruiting

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cervical Cancer

China
Frontier Biotechnologies Inc.

Completed

A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain

Chronic Low Back Pain

United States
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Alector Inc.

Completed

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Healthy | Frontotemporal Dementia

United States, Canada, United Kingdom
Alector Inc.
AbbVie

Recruiting

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Alzheimer's Disease

Australia, Spain, United States, Italy, Canada, Poland, United Kingdom, Germany
Novartis Pharmaceuticals

Completed

A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects

Hepatic Impairment

United States
Zhejiang University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Allakos Inc.

Completed

Study to Evaluate Multiple Doses in Patients With Nasal Polyposis

Nasal Polyposis

Belgium, United States, Germany, Netherlands, Spain, United Kingdom
Achilles Therapeutics UK Limited

Terminated

Long-Term Follow-Up Study of Patients Receiving ATL001

Melanoma | Advanced Non Small Cell Lung Cancer

United Kingdom
Ayala Pharmaceuticals, Inc,

Terminated

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer (TENACITY)

Triple Negative Breast Cancer

United States, Belgium, Israel, Spain, United Kingdom
Affiliated Hospital of Guangdong Medical University

Not yet recruiting

Safety and Efficacy Clinical Study of Severe Hemophilia B Treatment With KL001

Hemophilia B Without Inhibitor
Alector Inc.
AbbVie

Active, not recruiting

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

Alzheimer Disease

United States, Spain, France, Germany, Australia, Canada, Poland, Italy, Argentina, Netherlands, United Kingdom, New Zealand
Novartis Pharmaceuticals

Completed

Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Renal Impairment

Germany, Bulgaria
Novartis Pharmaceuticals

Active, not recruiting

De-escalation and TFR Study in CML Patients Treated With Nilotinib Followed by a Second Attempt After Nilotinib and Asciminib Combination (DANTE)

Chronic Myeloid Leukemia

Italy
Ayala Pharmaceuticals, Inc,

Completed

A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations (ACCURACY)

Adenoid Cystic Carcinoma

United States, Canada, France, United Kingdom, Israel, Netherlands
M.D. Anderson Cancer Center

Recruiting

AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer

Adenoid Cystic Carcinoma | Metastatic Adenoid Cystic Carcinoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP.

Chronic Myelogenous Leukemia

Spain, United Kingdom, Germany, Canada, Austria, France, Korea, Republic of, Greece, Singapore, Italy, Argentina, Poland, Vietnam, Malaysia, Oman, Brazil
Novartis Pharmaceuticals

Active, not recruiting

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation (AIM4CML)

Chronic Myelogenous Leukemia - Chronic Phase

United States
AmDerma
International Dermatology Research, Inc.

Completed

Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis

Plaque Psoriasis

Dominican Republic
Novartis Pharmaceuticals

Recruiting

Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE)

Chronic Myelogenous Leukemia - Chronic Phase

United States
Alector Inc.

Completed

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Healthy

United States
ABL Bio, Inc.
National OncoVenture

Completed

This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001

Advanced Solid Tumors

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy With Tyrosine Kinase Inhibitor

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
Alector Inc.

Completed

First in Human Study for Safety and Tolerability of AL003.

Healthy | Alzheimer Disease

United States, Australia
Alector Inc.

Completed

A Phase I Study for Safety and Tolerability of AL002.

Healthy | Alzheimer Disease

United States, United Kingdom, Australia
AmDerma

Completed

Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis

Actinic Keratosis

United States
Achilles Therapeutics UK Limited

Recruiting

ATL001 in Patients With Metastatic or Recurrent Melanoma

Melanoma

Spain, United Kingdom
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Chronic Myelogenous Leukemia

United States, United Kingdom, Hungary, Japan, Saudi Arabia, Australia, Germany, Canada, France, Netherlands, Spain, Lebanon, Turkey, Korea, Republic of, Argentina, Brazil, Bulgaria, Czechia, Israel, Italy, Mexico, Romania, Russian... and more
HK inno.N Corporation

Not yet recruiting

A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

Healthy

Korea, Republic of
Augusta University
H. Jean Khoury Cure CML Consortium

Recruiting

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase (ALERTCML)

Leukemia, Myeloid | Chronic Myeloid Leukemia, Chronic Phase | Adult CML | Leukemia,Myeloid, Chronic

United States
Allakos Inc.

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001

Atopy

United States
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Leukemia, Chronic Myelogenous

China
Frontier Biotechnologies Inc.

Completed

Tolerability, Safety and Pharmacokinetics of a Topical AB001 Patch in Healthy Subjects

Chronic Low Back Pain

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)

Medullary Thyroid Cancer | Pancreatic Neuroendocrine Tumor | Adrenal Cortical Carcinoma | Thymic Neuroendocrine Carcinoma

China
Baxalta now part of Shire

Completed

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

Hemophilia A

United States, France, Austria, United Kingdom, Germany, Belgium, Canada, Italy, Sweden
Novartis Pharmaceuticals

Completed

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL

Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Germany, Australia, Netherlands, Spain, Korea, Republic of, France, Japan, Italy, Singapore, United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
HK inno.N Corporation

Completed

Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians

Healthy

Korea, Republic of
Achilles Therapeutics UK Limited

Recruiting

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

Advanced Non Small Cell Lung Cancer

United States, Germany, France, Spain, United Kingdom
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults

Postmenopausal Osteoporosis

China
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Recruiting

Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Recruiting

A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) (ASC4START)

Philadelphia Chromosome-Positive Chronic Myeloid Leukemia

Singapore, France, Germany, United Arab Emirates, Greece, Italy, Czechia, Hungary, United States, India, Oman, Malaysia, Korea, Republic of, Turkey, Bulgaria, Canada, Slovakia, United Kingdom, Argentina, Jordan, Romania, South Africa and more
M.D. Anderson Cancer Center
Novartis Pharmaceuticals

Not yet recruiting

Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Philadelphia Chromosome-Positive

United States
Penwest Pharmaceuticals Co.

Terminated

Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Neuromuscular Disease

United Kingdom
Handok Inc.
ABL Bio, Inc.; Compass Therapeutics

Active, not recruiting

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

P1b: Advanced Solid Tumors | P2: Biliary Tract Cancer

Korea, Republic of
Penwest Pharmaceuticals Co.

Completed

Safety and Efficacy Study of A0001 in Subjects With Friedreich's Ataxia

Friedreich's Ataxia

United States

Search clinical trials for: AL001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations